Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
SGB-3383 in Healthy Volunteers
NCT06995326Phase 1Not yet recruiting
- Sponsor
- SanegeneBio
- Start
- Jun 2025
- Primary completion
- Aug 2026
- Modality
- Conjugated siRNA, Chemically Modified siRNA
01
Overview
Phase 1, randomised, double-blind trial in IgA nephropathy (IgAN), Complement 3 glomerulopathy (C3G), atypical hemolytic uremic syndrome (aHUS) and 2 more comparing SGB-3383 with Placebo (2 arms). Primary endpoint: Number of Participants with Adverse Events. Planned start Jun 2025; status: not yet recruiting.
02
Drugs
SGB-3383
03
Conditions
IgA nephropathy (IgAN)Complement 3 glomerulopathy (C3G)atypical hemolytic uremic syndrome (aHUS)paroxysmal nocturnal hemoglobinuria (PNH)immune complex-mediated membranoproliferative glomerulonephritis (IC-MPGN)
Beyond the preview
Go deeper on NCT06995326.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06995326.